These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37726786)

  • 1. The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.
    Divoux J; Florent R; Jacobs M; Lequesne J; Grellard JM; San C; Grossi S; Kerdja K; Clarisse B; Boudier G; Cherifi F; Briand M; Dolivet E; Johnson A; Dubois B; Harter V; Lacroix J; Raboutet C; Marie B; Rousseau N; Blanc-Fournier C; Vaur D; Figeac M; Poulain L; Weiswald LB; Emile G
    BMC Cancer; 2023 Sep; 23(1):883. PubMed ID: 37726786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ORGAVADS: establishment of tumor organoids from head and neck squamous cell carcinoma to assess their response to innovative therapies.
    Perréard M; Florent R; Divoux J; Grellard JM; Lequesne J; Briand M; Clarisse B; Rousseau N; Lebreton E; Dubois B; Harter V; Lasne-Cardon A; Drouet J; Johnson A; Le Page AL; Bazille C; Jeanne C; Figeac M; Goardon N; Vaur D; Micault E; Humbert M; Thariat J; Babin E; Poulain L; Weiswald LB; Bastit V
    BMC Cancer; 2023 Mar; 23(1):223. PubMed ID: 36894916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The OVAREX study: Establishment of ex vivo ovarian cancer models to validate innovative therapies and to identify predictive biomarkers.
    Thorel L; Divoux J; Lequesne J; Babin G; Morice PM; Florent R; Desmartin G; Lecouflet L; Marde Alagama C; Leconte A; Clarisse B; Briand M; Rouzier R; Gaichies L; Martin-Françoise S; Le Brun JF; Denoyelle C; Vigneron N; Jeanne C; Blanc-Fournier C; Leman R; Vaur D; Figeac M; Meryet-Figuiere M; Joly F; Weiswald LB; Poulain L; Dolivet E
    BMC Cancer; 2024 Jun; 24(1):701. PubMed ID: 38849726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma.
    Thorel L; Morice PM; Paysant H; Florent R; Babin G; Thomine C; Perréard M; Abeilard E; Giffard F; Brotin E; Denoyelle C; Villenet C; Sebda S; Briand M; Joly F; Dolivet E; Goux D; Blanc-Fournier C; Jeanne C; Villedieu M; Meryet-Figuiere M; Figeac M; Poulain L; Weiswald LB
    J Exp Clin Cancer Res; 2023 Oct; 42(1):260. PubMed ID: 37803448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.
    Pan B; Zhao D; Liu Y; Li N; Song C; Li N; Li X; Zhao Z
    In Vitro Cell Dev Biol Anim; 2021 May; 57(5):510-518. PubMed ID: 33950403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.
    Tang AH; Hoefer RA; Guye ML; Bear HD
    Cancer Drug Resist; 2022; 5(3):691-702. PubMed ID: 36176751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
    Wu SY; Xu Y; Chen L; Fan L; Ma XY; Zhao S; Song XQ; Hu X; Yang WT; Chai WJ; Guo XM; Chen XZ; Xu YH; Zhu XY; Zou JJ; Wang ZH; Jiang YZ; Shao ZM
    Mol Cancer; 2022 Mar; 21(1):84. PubMed ID: 35337339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
    Mei J; Liu X; Tian HX; Chen Y; Cao Y; Zeng J; Liu YC; Chen Y; Gao Y; Yin JY; Wang PY
    Clin Transl Med; 2024 Apr; 14(4):e1656. PubMed ID: 38664597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
    Deng J; Thennavan A; Shah S; Bagdatlioglu E; Klar N; Heguy A; Marier C; Meyn P; Zhang Y; Labbe K; Almonte C; Krogsgaard M; Perou CM; Wong KK; Adams S
    Breast Cancer Res Treat; 2021 Jan; 185(1):85-94. PubMed ID: 32949350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-Derived Triple-Negative Breast Cancer Organoids Provide Robust Model Systems That Recapitulate Tumor Intrinsic Characteristics.
    Bhatia S; Kramer M; Russo S; Naik P; Arun G; Brophy K; Andrews P; Fan C; Perou CM; Preall J; Ha T; Plenker D; Tuveson DA; Rishi A; Wilkinson JE; McCombie WR; Kostroff K; Spector DL
    Cancer Res; 2022 Apr; 82(7):1174-1192. PubMed ID: 35180770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
    Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
    Front Immunol; 2021; 12():749459. PubMed ID: 34603338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
    Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
    BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
    Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
    Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens.
    Parikh AY; Masi R; Gasmi B; Hanada KI; Parkhurst M; Gartner J; Sindiri S; Prickett T; Robbins P; Zacharakis N; Beshiri M; Kelly K; Rosenberg SA; Yang JC
    Cancer Immunol Immunother; 2023 Oct; 72(10):3149-3162. PubMed ID: 37368077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
    Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
    JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.